Phosphodiesterase type 5 (PDE5) inhibition improves object recognition memory: Indications for central and peripheral mechanisms

Neurobiology of Learning and Memory

Volumn 97, Issue 4, 2012, Pages 370-379

  Reneerkens, Olga A H ^a   Rutten, Kris ^a,d   Akkerman, Sven ^a   Blokland, Arjan ^a   Shaffer, Christopher L ^b   Menniti, Frank S ^c   Steinbusch, Harry W M ^a   Prickaerts, Jos ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b PFIZER INC   (United States)

^c Mnemosyne Pharmaceuticals Inc   (United States)

^d GRÜNENTHAL GMBH   (Germany)

Author keywords

Central and peripheral mechanisms; CGMP; Memory; Object recognition; Phosphodiesterase type 5; UK 343,664; Vardenafil

Indexed keywords

DIZOCILPINE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; SCOPOLAMINE; UK 343664; UNCLASSIFIED DRUG; VARDENAFIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFICACY; EXPLORATORY BEHAVIOR; MALE; MEMORY; MEMORY DISORDER; NONHUMAN; OBJECT RECOGNITION; RAT; RECOGNITION; TASK PERFORMANCE;

ANIMALS; BLOOD-BRAIN BARRIER; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DIZOCILPINE MALEATE; IMIDAZOLES; MALE; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PYRIMIDINONES; RATS; RATS, WISTAR; RECOGNITION (PSYCHOLOGY); SCOPOLAMINE HYDROBROMIDE; SULFONES; TRIAZINES;

EID: 84861186019     PISSN: 10747427     EISSN: 10959564     Source Type: Journal    
DOI: 10.1016/j.nlm.2012.02.008     Document Type: Article

References (66)

1. Abel S., Beaumont K.C., Crespi C.L., Eve M.D., Fox L., Hyland R., et al. Potential role for P-glycoprotein in the non-proportional pharmacokinetics of UK-343,664 in man. Xenobiotica 2001, 31:665-676.
2. Baek S.B., Bahn G., Moon S.J., Lee J., Kim K.H., Ko I.G., et al. The phosphodiesterase type-5 inhibitor, tadalafil, improves depressive symptoms, ameliorates memory impairment, as well as suppresses apoptosis and enhances cell proliferation in the hippocampus of maternal-separated rat pups. Neurosci Letters 2011, 488:26-30.
3. Barad M., Bourtchouladze R., Winder D.G., Golan H., Kandel E. Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. Proceedings of the National Academy of Sciences of the United States 1998, 95:15020-15025.
4. Baratti C.M., Boccia M.M. Effects of sildenafil on long-term retention of an inhibitory avoidance response in mice. Behavioural Pharmacology 1999, 10:731-737.
5. Bender A.T., Beavo J.A. Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use. Pharmacological Review 2006, 58:488-520.
6. Bliss T.V., Collingridge G.L. A synaptic model of memory: Long-term potentiation in the hippocampus. Nature 1993, 361:31-39.
7. Boccia M.M., Blake M.G., Krawczyk M.C., Baratti C.M. Sildenafil, a selective phosphodiesterase type 5 inhibitor, enhances memory reconsolidation of an inhibitory avoidance task in mice. Behavioural Brain Research 2011, 220:319-324.
8. Boess F.G., Hendrix M., van der Staay F.J., Erb C., Schreiber R., van Staveren W., et al. Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology 2004, 47:1081-1092.
9. Brown M.W., Aggleton J.P. Recognition memory: What are the roles of the perirhinal cortex and hippocampus?. Nature Reviews Neuroscience 2001, 2:51-61.
10. Cuadrado-Tejedor M., Hervias I., Ricobaraza A., Puerta E., Perez-Roldan J.M., Garcia-Barroso C., et al. Sildenafil restores cognitive function without affecting beta-amyloid burden in a mouse model of Alzheimer's disease. British Journal of Pharmacology 2011, 164:2029-2041.
11. de Bruin N.M., Prickaerts J., van Loevezijn A., Venhorst J., de Groote L., Houba P., et al. Two novel 5-HT6 receptor antagonists ameliorate scopolamine-induced memory deficits in the object recognition and object location tasks in Wistar rats. Neurobiology of Learning and Memory 2011, 96:392-402.
12. Devan B.D., Sierra-Mercado D., Jimenez M., Bowker J.L., Duffy K.B., Spangler E.L., et al. Phosphodiesterase inhibition by sildenafil citrate attenuates the learning impairment induced by blockade of cholinergic muscarinic receptors in rats. Pharmacology, Biochemistry and Behavior 2004, 79:691-699.
13. Domek-Lopacinska K., Strosznajder J.B. The effect of selective inhibition of cyclic GMP hydrolyzing phosphodiesterases 2 and 5 on learning and memory processes and nitric oxide synthase activity in brain during aging. Brain Research 2008, 1216:68-77.
14. Ennaceur A. One-trial object recognition in rats and mice. Methodological and theoretical issues. Behavioural Brain Research 2010, 215:244-254.
15. Ennaceur A., Cavoy A., Costa J.C., Delacour J. A new one-trial test for neurobiological studies of memory in rats. II: Effects of piracetam and pramiracetam. Behavioural Brain Research 1989, 33:197-207.
16. Ennaceur A., Delacour J. A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behavioural Brain Research 1988, 31:47-59.
17. Frey U., Huang Y.Y., Kandel E.R. Effects of cAMP simulate a late stage of LTP in hippocampal CA1 neurons. Science 1993, 260:1661-1664.
18. Ghofrani H.A., Osterloh I.H., Grimminger F. Sildenafil: From angina to erectile dysfunction to pulmonary hypertension and beyond. Nature Reviews Drug Discovery 2006, 5:689-702.
19. Giordano D., De Stefano M.E., Citro G., Modica A., Giorgi M. Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain. Biochimica et Biophysica Acta 2001, 1539:16-27.
20. Goff D.C., Cather C., Freudenreich O., Henderson D.C., Evins A.E., Culhane M.A., et al. A placebo-controlled study of sildenafil effects on cognition in schizophrenia. Psychopharmacology (Berl) 2009, 202:411-417.
21. Halene T.B., Siegel S.J. PDE inhibitors in psychiatry-future options for dementia, depression and schizophrenia?. Drug Discovery Today 2007, 12:870-878.
22. Hitchcock S.A., Pennington L.D. Structure-brain exposure relationships. Journal of Medicinal Chemistry 2006, 49:7559-7583.
23. Kiss, T., Hoffmann, W. E., & Hajos, M. (2010). Delta oscillation and short-term plasticity in the rat medial prefrontal cortex: modelling NMDA hypofunction of schizophrenia. International Journal of Neuropsychopharmacology, 1-14.
24. Kleppisch, T., & Feil, R. (2009). cGMP signalling in the mammalian brain: Role in synaptic plasticity and behaviour. Handbook of Experimental Pharmacology, 549-579.
25. Klinkenberg I., Blokland A. The validity of scopolamine as a pharmacological model for cognitive impairment: A review of animal behavioral studies. Neuroscience and Biobehavioral Reviews 2010, 34:1307-1350.
26. Kotera J., Fujishige K., Omori K. Immunohistochemical localization of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in rat tissues. Journal of Histochemistry and Cytochemistry 2000, 48:685-693.
27. Kotera J., Yanaka N., Fujishige K., Imai Y., Akatsuka H., Ishizuka T., et al. Expression of rat cGMP-binding cGMP-specific phosphodiesterase mRNA in Purkinje cell layers during postnatal neuronal development. European Journal of Biochemistry 1997, 249:434-442.
28. Kruse L.S., Sandholdt N.T., Gammeltoft S., Olesen J., Kruuse C. Phosphodiesterase 3 and 5 and cyclic nucleotide-gated ion channel expression in rat trigeminovascular system. Neuroscience Letters 2006, 404:202-207.
29. Kruuse C., Hansen A.E., Larsson H.B., Lauritzen M., Rostrup E. Cerebral haemodynamic response or excitability is not affected by sildenafil. Journal of Cerebral Blood Flow and Metabolism 2009, 29:830-839.
30. Kruuse C., Thomsen L.L., Birk S., Olesen J. Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain 2003, 126:241-247.
31. Kruuse C., Thomsen L.L., Jacobsen T.B., Olesen J. The phosphodiesterase 5 inhibitor sildenafil has no effect on cerebral blood flow or blood velocity, but nevertheless induces headache in healthy subjects. Journal of Cerebral Blood Flow and Metabolism 2002, 22:1124-1131.
32. Lakics V., Karran E.H., Boess F.G. Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology 2010, 59:367-374.
33. Menniti F.S., Faraci W.S., Schmidt C.J. Phosphodiesterases in the CNS: Targets for drug development. Nature Reviews Drug Discovery 2006, 5:660-670.
34. Menniti F.S., Ren J., Coskran T.M., Liu J., Morton D., Sietsma D.K., et al. Phosphodiesterase 5A inhibitors improve functional recovery after stroke in rats: Optimized dosing regimen with implications for mechanism. Journal of Pharmacology and Experimental Therapeutics 2009, 331:842-850.
35. Moghaddam B., Jackson M.E. Glutamatergic animal models of schizophrenia. Annals of the New York Academy of Sciences 2003, 1003:131-137.
36. Mumby D.G. Perspectives on object-recognition memory following hippocampal damage: Lessons from studies in rats. Behavioural Brain Research 2001, 127:159-181.
37. Nakamizo, T., Kawamata, J., Yoshida, K., Kawai, Y., Kanki, R., Sawada, H., et al. (2003). Phosphodiesterase inhibitors are neuroprotective to cultured spinal motor neurons. 71, 485-495.
38. Prickaerts J., Koopmans G., Blokland A., Scheepens A. Learning and adult neurogenesis: Survival with or without proliferation?. Neurobiology of Learning and Memory 2004, 81:1-11.
39. Prickaerts J., Sik A., van der Staay F.J., de Vente J., Blokland A. Dissociable effects of acetylcholinesterase inhibitors and phosphodiesterase type 5 inhibitors on object recognition memory: Acquisition versus consolidation. Psychopharmacology (Berl) 2005, 177:381-390.
40. Prickaerts J., Sik A., van Staveren W.C., Koopmans G., Steinbusch H.W., van der Staay F.J., et al. Phosphodiesterase type 5 inhibition improves early memory consolidation of object information. Neurochemistry International 2004, 45:915-928.
41. Prickaerts J., Steinbusch H.W., Smits J.F., de Vente J. Possible role of nitric oxide-cyclic GMP pathway in object recognition memory: Effects of 7-nitroindazole and zaprinast. European Journal of Pharmacology 1997, 337:125-136.
42. Prickaerts J., van Goethem N.P., Chesworth R., Shapiro G., Boess F.G., Methfessel C., et al. EVP-6124, a novel and selective alpha7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of alpha7 nicotinic acetylcholine receptors. Neuropharmacology 2012, 62:1099-1110.
43. Prickaerts J., van Staveren W.C., Sik A., Markerink-van Ittersum M., Niewohner U., van der Staay F.J., et al. Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic GMP levels in the rat. Neuroscience 2002, 113:351-361.
44. Puzzo D., Sapienza S., Arancio O., Palmeri A. Role of phosphodiesterase 5 in synaptic plasticity and memory. Neuropsychiatric Disease and Treatment 2008, 4:371-387.
45. Puzzo D., Staniszewski A., Deng S.X., Privitera L., Leznik E., Liu S., et al. Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load in an Alzheimer's disease mouse model. Journal of Neuroscience 2009, 29:8075-8086.
46. Reneerkens O.A., Rutten K., Steinbusch H.W., Blokland A., Prickaerts J. Selective phosphodiesterase inhibitors: A promising target for cognition enhancement. Psychopharmacology (Berl) 2009, 202:419-443.
47. Reyes-Irisarri E., Markerink-Van Ittersum M., Mengod G., de Vente J. Expression of the cGMP-specific phosphodiesterases 2 and 9 in normal and Alzheimer's disease human brains. European Journal of Neuroscience 2007, 25:3332-3338.
48. Rutten K., Lieben C., Smits L., Blokland A. The PDE4 inhibitor rolipram reverses object memory impairment induced by acute tryptophan depletion in the rat. Psychopharmacology (Berl) 2007, 192:275-282.
49. Rutten K., Prickaerts J., Blokland A. Rolipram reverses scopolamine-induced and time-dependent memory deficits in object recognition by different mechanisms of action. Neurobiology of Learning and Memory 2006, 85:132-138.
50. Rutten K., Prickaerts J., Hendrix M., van der Staay F.J., Sik A., Blokland A. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: Studies using selective phosphodiesterase type 2, 4 and 5 inhibitors. European Journal of Pharmacology 2007, 558:107-112.
51. Rutten K., Van Donkelaar E.L., Ferrington L., Blokland A., Bollen E., Steinbusch H.W., et al. Phosphodiesterase inhibitors enhance object memory independent of cerebral blood flow and glucose utilization in rats. Neuropsychopharmacology 2009, 34:1914-1925.
52. Rutten K., Vente J.D., Sik A., Ittersum M.M., Prickaerts J., Blokland A. The selective PDE5 inhibitor, sildenafil, improves object memory in Swiss mice and increases cGMP levels in hippocampal slices. Behavioural Brain Research 2005, 164:11-16.
53. Schreiber R., Vivian J., Hedley L., Szczepanski K., Secchi R.L., Zuzow M., et al. Effects of the novel 5-HT(6) receptor antagonist RO4368554 in rat models for cognition and sensorimotor gating. European Neuropsychopharmacology 2007, 17:277-288.
54. Schultheiss D., Muller S.V., Nager W., Stief C.G., Schlote N., Jonas U., et al. Central effects of sildenafil (Viagra) on auditory selective attention and verbal recognition memory in humans: a study with event-related brain potentials. World Journal of Urology 2001, 19:46-50.
55. Shim Y.S., Pae C.U., Kim S.W., Kim H.W., Kim J.C., Koh J.S. Effects of repeated dosing with Udenafil (Zydena) on cognition, somatization and erection in patients with erectile dysfunction: A pilot study. International Journal of Impotence Research 2011, 23:109-114.
56. Shimizu-Albergine M., Rybalkin S.D., Rybalkina I.G., Feil R., Wolfsgruber W., Hofmann F., et al. Individual cerebellar Purkinje cells express different cGMP phosphodiesterases (PDEs): In vivo phosphorylation of cGMP-specific PDE (PDE5) as an indicator of cGMP-dependent protein kinase (PKG) activation. Journal of Neuroscience 2003, 23:6452-6459.
57. Sik A., van Nieuwehuyzen P., Prickaerts J., Blokland A. Performance of different mouse strains in an object recognition task. Behavioural Brain Research 2003, 147:49-54.
58. Son H., Lu Y.F., Zhuo M., Arancio O., Kandel E.R., Hawkins R.D. The specific role of cGMP in hippocampal LTP. Learning & Memory 1998, 5:231-245.
59. van der Staay F.J., Rutten K., Barfacker L., Devry J., Erb C., Heckroth H., et al. The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents. Neuropharmacology 2008, 55:908-918.
60. van der Staay F.J., Rutten K., Erb C., Blokland A. Effects of the cognition impairer MK-801 on learning and memory in mice and rats. Behavioural Brain Research 2011, 220:215-229.
61. van Donkelaar E.L., Rutten K., Blokland A., Akkerman S., Steinbusch H.W., Prickaerts J. Phosphodiesterase 2 and 5 inhibition attenuates the object memory deficit induced by acute tryptophan depletion. European Journal of Pharmacology 2008, 600:98-104.
62. Van Staveren W.C., Steinbusch H.W., Markerink-Van Ittersum M., Repaske D.R., Goy M.F., Kotera J., et al. MRNA expression patterns of the cGMP-hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain. Journal of Comparative Neurology 2003, 467:566-580.
63. Vardigan J.D., Huszar S.L., McNaughton C.H., Hutson P.H., Uslaner J.M. MK-801 produces a deficit in sucrose preference that is reversed by clozapine, D-serine, and the metabotropic glutamate 5 receptor positive allosteric modulator CDPPB: Relevance to negative symptoms associated with schizophrenia?. Pharmacology, Biochemistry and Behavior 2010, 95:223-229.
64. Walker D.K., Beaumont K.C., Comby P., Evans K.M., Gedge J.I., Halliday R.C., et al. Pharmacokinetics and metabolism of a selective PDE5 inhibitor (UK-343,664) in rat and dog. Xenobiotica 2001, 31:651-664.
65. Winters B.D., Bussey T.J. Transient inactivation of perirhinal cortex disrupts encoding, retrieval, and consolidation of object recognition memory. Journal of Neuroscience 2005, 25:52-61.
66. Zhang H.T., Crissman A.M., Dorairaj N.R., Chandler L.J., O'Donnell J.M. Inhibition of cyclic AMP phosphodiesterase (PDE4) reverses memory deficits associated with NMDA receptor antagonism. Neuropsychopharmacology 2000, 23:198-204.